Relay Therapeutics - About the company
Relay Therapeutics is a public company based in Cambridge (United States), founded in 2016 by David E Shaw. It operates as a Developer of drug discovery platform and study protein motion. Relay Therapeutics has raised $520M in funding from investors like Third Rock Ventures, D. E. Shaw Research and BVF Partners. The company has 3352 active competitors, including 1127 funded and 781 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Relay Therapeutics is a developer of a drug discovery platform and study protein motion. The company’s drug discovery engine provides 3D visuals on the mobility of a protein to study or analyze the function of protein-based on its motion. It also enables the researchers to study the ligand-binding pockets present in the protein and detect ligand-protein binding interactions. The company’s initial program focuses on developing therapeutics in oncology.
- Website
- relaytx.com
- Social
- Email ID
- *****@relaytx.com
- Phone Number
- +1 **********
- Registered Address
- Cambridge, Massachusetts
Key Metrics
Founded Year
2016
Location
Cambridge, United States
Stage
Public
Total Funding
$520M in 4 rounds
Latest Funding Round
Investors
Ranked
16th among 3352 active competitors
Annual Revenue
$10M - $50M as on Dec 31, 2025
Employee Count
223 as on Aug 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Relay Therapeutics
Relay Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Relay Therapeutics, Inc. CIN: 473923475 , United States, Active | Dec 31, 2015 | $10M - $50M (As on Dec 31, 2025) | 261 (As on Dec 31, 2024) | - |
Relay Therapeutics's IPO details
Relay Therapeutics got listed on Jul 16, 2020.
Click here to take a look at Relay Therapeutics's IPO in detail
Sign up to download Relay Therapeutics' company profile
Relay Therapeutics's funding and investors
Relay Therapeutics has raised a total funding of $520M over 4 rounds. Its first funding round was on Sep 14, 2016. Relay Therapeutics has 19 institutional investors.
Here is the list of recent funding rounds of Relay Therapeutics:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 10, 2024 | 6355973 | Post IPO | 5643460 | 2602632 | 8903606 | 8266859 |
Dec 20, 2018 | 7776299 | Series C | 8705957 | 7058382 | 2597295 | |
Dec 14, 2017 | 6542769 | Series B | 6939563 | 6533973 |
Access funding benchmarks and valuations. Sign up today!View details of Relay Therapeutics's funding rounds and investors
Relay Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Relay Therapeutics is David E Shaw.
Here are the details of Relay Therapeutics' key team members:
- David E Shaw: Co-Founder of Relay Therapeutics and founder of 2 other companies, D. E. Shaw Research and The D. E. Shaw Group. Contact Info: 1 email address
View details of Relay Therapeutics's Founder profiles and Board Members
Relay Therapeutics' employee count trend
Relay Therapeutics has 223 employees as of Aug 26. Here is Relay Therapeutics's employee count trend over the years:
Uncover Relay Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Relay Therapeutics's Competitors and alternates
Top competitors of Relay Therapeutics include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Relay Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
16th | Relay Therapeutics 2016, Cambridge (United States), Public | Developer of drug discovery platform and study protein motion | $520M | 70/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Relay Therapeutics's competitors? Click here to see the top ones
Relay Therapeutics's Investments and acquisitions
Relay Therapeutics has acquired ZebiAI. Relay Therapeutics has not made any investments as of now.Reports related to Relay Therapeutics
Here is the latest report on Relay Therapeutics's sector:
News related to Relay Therapeutics
Filter this listMedia has covered Relay Therapeutics for a total of 14 events in the last 1 year, 9 of them have been about company updates.
•
•
Relay Therapeutics (RLAY) CEO trades shares, keeps over 615K direct holdingsStocktitan•Jul 08, 2026•Relay Therapeutics
•
Seven Fleet Capital Management LP Makes New Investment in Relay Therapeutics, Inc. $RLAYThelincolnianonline•Jun 19, 2026•Relay Therapeutics
•
Relay Therapeutics Announces Pricing of Public Offering of Common StockGlobeNewswire•May 21, 2026•Relay Therapeutics
•
•
A Look At Relay Therapeutics (RLAY) Valuation After Recent Share Price PullbackSimply Wall St•May 20, 2026•Relay Therapeutics
•
Relay Therapeutics Reports Initial Phase II ReInspire Trial Findings for Zovegalisibclinicaltrialsarena.com•May 20, 2026•Relay Therapeutics
•
•
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate UpdatesGlobeNewswire•May 05, 2026•Relay Therapeutics
•
Commodore Capital LP Raises Stake in Relay Therapeutics, Inc.MarketBeat•Mar 15, 2026•Relay Therapeutics, Commodore Capital
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Relay Therapeutics
Explore our recently published companies
- Vanguard Madison - Madison based, Unfunded company
- MTi - Mingothings - Spain based, 2016 founded, Unfunded company
- Naples - 2019 founded, Unfunded company
- Klay Media - Beverly Hills based, Unfunded company
- STI Biotechnology - Maen Roch based, 2005 founded, Acquired company
- Glycomyr - Ames based, 2008 founded, Unfunded company
